Remifentanil and Nitroprusside for Controlled Hypotension
Information source: Jeju National University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypotension, Controlled
Intervention: remifentanil (Drug); nitroprusside (Drug)
Phase: N/A
Status: Completed
Sponsored by: Jeju National University School of Medicine
Summary
The purpose of this study is the comparison of the cardiovascular effects of remifentanil
and nitroprusside for controlled hypotension
Clinical Details
Official title: The Comparison of the Cardiovascular Effects of Remifentanil and Nitroprusside for Controlled Hypotension
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Primary outcome: Cardiac index
Secondary outcome: Total peripheral resistance index
Eligibility
Minimum age: 20 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who underwent endoscopic sinus surgery
Exclusion Criteria:
- patient who took any drug to influence this study
- patient with cardiovascular disease, renal disease or liver disease
Locations and Contacts
Jeju National University Hospital, Jeju-si, Jeju Special Self-Governing Province 690-767, Korea, Republic of
Additional Information
Starting date: June 2012
Last updated: December 3, 2013
|